TrialBritish journal of haematology2014

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia.

Michael W Deininger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.